Abstract
The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The escalating number of SARS-CoV-2-infected individuals has conferred the viral spread with the status of global pandemic. However, there are no prophylactic or therapeutic drugs available on the market to treat COVID-19, although several drugs have been approved. Recently, two articles using the comparative viral-human protein-protein interaction map revealed that the sigma-1 receptor in the endoplasmic reticulum plays an important role in SARS-CoV-2 replication in cells. Knockout and knockdown of SIGMAR1 (sigma-1 receptor, encoded by SIGMAR1) caused robust reductions in SARS-CoV-2 replication, which indicates that the sigma-1 receptor is a key therapeutic target for SARS-CoV-2 replication. Interestingly, a recent clinical trial demonstrated that treatment with the antidepressant fluvoxamine, which has a high affinity at the sigma-1 receptor, could prevent clinical deterioration in adult outpatients infected with SARS-CoV-2. In this review, we discuss the brief history of the sigma-1 receptor and its role in SARS-CoV-2 replication in cells. Here, we propose repurposing of traditional central nervous system (CNS) drugs that have a high affinity at the sigma-1 receptor (i.e., fluvoxamine, donepezil, ifenprodil) for the treatment of SARS-CoV-2-infected patients. Finally, we discussed the potential of other CNS candidates such as cutamesine and arketamine.
Keywords: Endoplasmic reticulum; Replication; Sigma-1 receptor.
【저자키워드】 sigma-1 receptor., Endoplasmic reticulum, Replication, 【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, coronavirus, clinical trial, drug, Prophylactic, novel coronavirus disease, severe acute respiratory syndrome Coronavirus, viral spread, Novel coronavirus, Endoplasmic reticulum, Replication, global pandemic, Viral, cells, fluvoxamine, Central nervous system, receptor, respiratory, CNS, protein-protein interaction, SARS-CoV-2 replication, antidepressant, Clinical deterioration, therapeutic target, acute respiratory syndrome, knockout, cutamesine, donepezil, arketamine, ifenprodil, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, status, infected individuals, market, high affinity, candidate, adult outpatients, treat, article, knockdown, SARS-CoV-2-infected patients, SARS-CoV-2-infected individuals, sigma, SIGMAR1, Prevent, robust, caused, approved, indicate, demonstrated, reductions in, adult outpatient, infected with SARS-CoV-2, SARS-CoV-2-infected individual, therapeutic drug, 【제목키워드】 COVID-19, repurposing, drug, CNS, treat,